Terms: = Prostate cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Clinical Outcome
7 results:
1. Immune Checkpoints, Inhibitors and Radionuclides in prostate cancer: Promising Combinatorial Therapy Approach.
Kgatle MM; Boshomane TMG; Lawal IO; Mokoala KMG; Mokgoro NP; Lourens N; Kairemo K; Zeevaart JR; Vorster M; Sathekge MM
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921181
[TBL] [Abstract] [Full Text] [Related]
2. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer.
Amori G; Sugawara E; Shigematsu Y; Akiya M; Kunieda J; Yuasa T; Yamamoto S; Yonese J; Takeuchi K; Inamura K
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):767-774. PubMed ID: 33558663
[TBL] [Abstract] [Full Text] [Related]
3. B7-H4 is a potential prognostic biomarker of prostate cancer.
Li H; Piao L; Liu S; Cui Y; Xuan Y
Exp Mol Pathol; 2020 Jun; 114():104406. PubMed ID: 32088189
[TBL] [Abstract] [Full Text] [Related]
4. Global levels of histone modifications predict prognosis in different cancers.
Seligson DB; Horvath S; McBrian MA; Mah V; Yu H; Tze S; Wang Q; Chia D; Goodglick L; Kurdistani SK
Am J Pathol; 2009 May; 174(5):1619-28. PubMed ID: 19349354
[TBL] [Abstract] [Full Text] [Related]
5. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
Wei Y; Xia W; Zhang Z; Liu J; Wang H; Adsay NV; Albarracin C; Yu D; Abbruzzese JL; Mills GB; Bast RC; Hortobagyi GN; Hung MC
Mol Carcinog; 2008 Sep; 47(9):701-6. PubMed ID: 18176935
[TBL] [Abstract] [Full Text] [Related]
6. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.
Roth TJ; Sheinin Y; Lohse CM; Kuntz SM; Frigola X; Inman BA; Krambeck AE; McKenney ME; Karnes RJ; Blute ML; Cheville JC; Sebo TJ; Kwon ED
Cancer Res; 2007 Aug; 67(16):7893-900. PubMed ID: 17686830
[TBL] [Abstract] [Full Text] [Related]
7. Global histone modification patterns predict risk of prostate cancer recurrence.
Seligson DB; Horvath S; Shi T; Yu H; Tze S; Grunstein M; Kurdistani SK
Nature; 2005 Jun; 435(7046):1262-6. PubMed ID: 15988529
[TBL] [Abstract] [Full Text] [Related]
